RVL Pharmaceuticals Inc. and its affiliates (together, "RVL") announced strong first-quarter performance, with total revenue ...

Study approval enables Rett REVOLUTION and Pitt Hopkins clinical programs to commence patient recruitment with first dosing expected in January 2026. BOSTON--(BUSINESS WIRE)--Unravel Biosciences, Inc.

Unravel Biosciences, Inc., ("Unravel"), a clinical stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform, today announced the first ...

RVL Pharmaceuticals plc's (NASDAQ:RVLP) several operating subsidiaries are filing for bankruptcy in a prepackaged deal with lender Athyrium Capital and other key stakeholders. The reorganization will ...

RVL Pharmaceuticals PLC (RVLP) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.15 per share a year ago. These ...

Good day and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

Good day, and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

RVL Pharmaceuticals PLC (RVLP) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago. These ...